Jensen Huang Scandal Raises Questions Over Nvidia’s Medical AI Empire

Platform expansion runs from drug discovery to surgical robots

Attention turns to fate of healthcare chief Powell

Attention is turning to the future of Nvidia’s healthcare business after Chief Executive Officer Jensen Huang resigned amid a personal scandal. Kimberly Powell, the vice president tied by media reports to allegations of an inappropriate relationship with Huang, has been a key figure in the company’s medical and life-sciences operations. With Nvidia replacing its top executive and uncertainty also surrounding the head of healthcare, the command structure of its medical AI business and the direction of external partnerships could change.

Nvidia announced on November 12 that Huang had resigned and Chief Financial Officer Colette Kress had been named interim CEO. The resignation came a day after The New York Times reported allegations about Huang’s relationship with Powell.

Nvidia’s healthcare business

The operation often referred to as Nvidia Healthcare is the company’s hardware and software business for the medical and life-sciences industries. Rather than selling drugs directly or running hospitals, Nvidia supplies graphics processing units and development platforms that enable drugmakers, medical-device companies, hospitals and research institutions to develop and use AI.

Its business spans drug discovery, genomics, medical imaging, medical devices and robotics, and digital health. That allows Nvidia technology to be applied across multiple points in healthcare, from identifying drug candidates in the lab to analyzing images and operating medical devices in hospitals.

A core platform in drug discovery is BioNeMo. It helps researchers build AI models trained on biological data and supports molecular design as well as prediction of protein structures and binding.

Parabricks, Nvidia’s genomics analysis software, is used to process large-scale sequencing data on GPUs and analyze genetic variation.

In medical imaging, the open-source development framework MONAI is central. It supports training for medical imaging AI models as well as image segmentation and registration. Nvidia says MONAI has been downloaded more than 8 million times and used in more than 4,000 projects.

The company has also expanded into medical devices and robotics. Holoscan provides the foundation for real-time processing of imaging and sensor data, while Isaac for Healthcare supports the design and validation of medical robots and equipment in virtual environments. In digital health, Nvidia has expanded by offering tools to develop AI agents that assist clinical research and healthcare workers.

Up to $1 billion co-investment with Lilly

The importance of Nvidia’s healthcare business is also reflected in its partners and the scale of investment. Nvidia said in January that it would establish a joint AI innovation lab with Eli Lilly and jointly invest as much as $1 billion over the next five years in talent, infrastructure and computing. The plan is to combine Lilly’s biology and pharmaceutical specialists with Nvidia’s AI researchers and engineers to accelerate drug development.

The company has also moved into autonomous imaging technology with GE HealthCare. The two companies said in March 2025 that they would develop autonomous X-ray technology and ultrasound applications. GE HealthCare is using Nvidia’s simulation platform to create virtual versions of sensors, human anatomy and medical environments.

Other partners include clinical-development and medical-data company IQVIA, genomics company Illumina, U.S. medical institution Mayo Clinic and life-sciences research organization Arc Institute. Nvidia said last year that it would work with those groups to apply generative AI and agentic AI to drug development, genomics research and healthcare services. In particular, it said IQVIA would use more than 64 petabytes of information and industry expertise to build customized AI models and solutions supporting research and clinical development.

The market Nvidia is targeting through healthcare is not a specific diagnostic product or a single drug. It is the business of supplying the computing power and software needed as drugmakers, hospitals and medical-device companies adopt AI. That structure gives Nvidia a significant competitive advantage because its partners provide medical expertise and data while the company supplies a common technology foundation that can scale across the healthcare industry.

Eyes on Powell’s future

Powell has long led Nvidia’s medical AI and healthcare business. She joined the company in 2008 and worked to expand the use of GPUs in medical imaging. She became vice president of healthcare in 2017. Her current remit covers the company’s hardware and software business across medical imaging, life sciences, drug discovery and healthcare analytics.

That is why the affair allegations have become a factor for the healthcare business. If Powell’s role changes in addition to Huang’s departure, the two pillars linking companywide strategic decision-making and execution in the healthcare unit could be adjusted at the same time.

Industry participants expect any early signs of strain to show up first not in the performance of existing GPUs or already deployed software, but in decisions on new partnerships and investments. In projects such as the joint lab with Lilly, which require years of staffing and resources, the key question is whether investment schedules and lines of responsibility can be maintained after the management reshuffle.

Nvidia is emphasizing business continuity. In announcing the leadership change, the board said it expects operations, commitments to customers and the product roadmap to continue without interruption.

Ultimately, experts say the fate of Nvidia’s medical AI empire will be determined less by the scandal itself than by management’s response afterward. Powell’s role, changes in the healthcare organization’s command structure and the execution schedule for major joint research and investment projects are the main issues to watch.

Choi Ji-hee, Hankyung.com reporter mymasaki@hankyung.com